Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12838326 | 1.00 | FKBP1A (0.35) | FKBP1AKCNH3 | |
| SCHEMBL13779620 | 0.76 | FKBP1A (0.39) | FKBP1A | |
| SCHEMBL24863497 | 0.73 | KCNH3 (0.34) | KCNH3 | |
| SCHEMBL22982417 | 0.72 | POLB (0.33) | FKBP1AKCNH3 | |
| SCHEMBL21245109 | 0.72 | POLB (0.33) | FKBP1AKCNH3 | |
| SCHEMBL22982303 | 0.72 | POLB (0.33) | FKBP1AKCNH3 | |
| SCHEMBL19598406 | 0.72 | FKBP1A (0.31) | FKBP1AKCNH3 | |
| SCHEMBL16727350 | 0.70 | FKBP1A (0.34) | FKBP1AKCNH3 | |
| SCHEMBL12070430 | 0.70 | CCR2 (0.33) | — | |
| SCHEMBL12070429 | 0.70 | CCR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | PROGEN PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7491849-B2 | Oligoamine compounds and derivatives thereof for cancer therapy | PROGEN PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7453011-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124832-A1 | OLIGOAMINE COMPOUNDS AND DERIVATIVES THEREOF FOR CANCER THERAPY | THOP1, OAT, DUT | FKBP1A 4145/4885KCNH3 4614/4885 |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | FKBP1A 1218/4885KCNH3 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.